Hepatitis
The Pharmacy Times® Hepatitis resource center provides clinical news and articles, pertaining to the Food and Drug Administration approved therapies to treat Hepatitis A, B, and C. Additionally, pharmacists will find coverage from pertinent conferences and meetings, videos, podcasts, and other associated content.
What can we help you find?
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-06-02_AFD37552-D5FD-4121-810F-1AA3C7D775AE_4_5005_c.jpeg)
Although HCV is now curable, there are varying factors that must be considered prior to starting treatment.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-05-04_liver_man.jpg)
Although lifesaving drugs became available around 1998 to treat hepatitis C, they were expensive, which limited access for some patients.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-04-23_AFD37552-D5FD-4121-810F-1AA3C7D775AE_4_5005_c.jpeg)
The 2 most common, recommended, and simplified treatments for HCV are glecaprevir/pibrentasvir (Mavyret) and sofosbuvir/velpatasvir (Epclusa).
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-03-02_Screen_Shot_2020-03-02_at_4.05.06_PM.png)
A review of the common misconceptions of hepatitis C reviewed by the experts in the field.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-03-02_Screen_Shot_2020-03-02_at_1.35.22_PM.png)
The panel of experts in the management of hepatitis C discuss the syringe exchange programs in different states.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-02-28_Screen_Shot_2020-02-28_at_4.26.48_PM.png)
Hepatitis C specialists identify the different ways hepatitis C virus can be transmitted.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-02-28_Screen_Shot_2020-02-28_at_4.03.59_PM.png)
A review of the patient education required to empower the patients in understanding who needs annual screening.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-03-19_FDA5-644px.jpg)
The drug was previously approved to treat HCV in adults
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-02-28_Screen_Shot_2020-02-28_at_3.42.32_PM.png)
Experts in the management of hepatitis C provide an understanding for when to screen annually and why pregnant women should be screened.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-02-28_Screen_Shot_2020-02-28_at_2.25.01_PM.png)
A review of the current screening recommendations for hepatitis C by experts in the field of hepatitis C.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-02-28_Screen_Shot_2020-02-28_at_11.49.43_AM.png)
The panel of experts in hepatitis C continue to discuss the development of hepatocellcular carcinoma in untreated patients.
Experts in the management of hepatitis C identify some of the complications of the disease, particularly cirrhosis and decompensated cirrhosis.